Irbesartan and valsartan, which is more effective? As a clinical pharmacist, I will talk about the antihypertensive drugs Irbesartan and Valsartan from the two aspects of drug characteristics and clinical applications, what is the difference? How to choose? The choice of similar drugs may be the most concerned about the majority of hypertensive friends, the most entangled things, seem to be similar, may really do not know with which one is better? In fact, there are some subtle differences between the two, we should see the focus of the two on target organ protection.

First of all, both Irbesartan and valsartan belong to the angiotensin II receptor antagonist, and the main antihypertensive mechanism is the same, both through the antagonism of the binding of angiotensin II to angiotensin II type 1 receptor, thus inhibiting angiotensin II vasoconstriction, promoting vascular hyperplasia and atherosclerosis, promoting cardiomyocyte hyperplasia and ventricular hypertrophy, releasing aldosterone to promote water-sodium retention, reducing renal blood flow and reducing sodium excretion and other bad effects.

In turn, it lowers blood pressure, reduces cardiac afterload, reverses left ventricular hypertrophy, inhibits thickening of blood vessel walls, resists atherosclerosis, protects heart, brain, and kidney functions, and prevents and treats hypertension, stroke, heart failure, myocardial infarction, and kidney failure.

Irbesartan bioavailability is 60%-80%, valsartan bioavailability is 23%. Irbesartan and valsartan have the same onset of action time, both for 2 hours, that is, 2 hours after taking the drug can be seen to lower blood pressure, both can reach the maximum antihypertensive effect in 4-6 hours, the antihypertensive effect can be maintained for 24 hours, that is, once a day to take can.

Irbesartan's blood levels will drop by half after 11-15 hours in the body, while valsartan's blood levels drop by half in 6-8 hours. Both Irbesartan and Valsartan are mainly excreted from the bile duct into the intestines in the form of a prototype through the liver, about 80% is excreted in the form of feces, and the rest is excreted through the kidneys. It can be seen that both are suitable for patients with renal dysfunction, as they are mainly excreted through the liver and have less effect on the kidneys.

Irbesartan, the original drug is produced by the French pharmaceutical company Serofi under the trade name of Ambevi. In addition to the treatment of essential hypertension, it is also used in the treatment of hypertension combined with type 2 diabetic nephropathy.

A large body of evidence-based medical evidence shows that Irbesartan can reduce urinary protein, increase creatinine clearance, reduce renal damage and protect renal function. In patients with hypertension combined with type 2 diabetes mellitus, the initial dose is 150mg and gradually increased to 300mg as a better maintenance dose for the treatment of nephropathy. It is more suitable for patients with hypertension combined with diabetic nephropathy.

Valsartan, the original drug, is manufactured by the Swiss pharmaceutical company Novartis under the trade name Devin. In addition to treating mild to moderate hypertension, it is also used to reduce cardiovascular events in patients with hypertension combined with heart failure and hypertension combined with myocardial infarction. Sartans, which reduce systemic vascular resistance, decrease cardiac preload and increase cardiac output, while preventing and reversing ventricular remodeling.

The Guidelines for the Rational Use of Medications in Heart Failure (2nd Edition) states that the three sartans, valsartan, losartan, and candesartan, have the strongest evidence of being effective in reducing the lethality and morbidity of heart failure. This is not to say that Irbesartan does not have a role, but to say that if it is hypertension with heart failure, heart attack patients, Irbesartan and valsartan two choose one, certainly choose the evidence-based medicine evidence is more adequate valsartan.

In general, Irbesartan and Valsartan, in terms of drug action characteristics, including antihypertensive onset of action time, maintenance time, drug metabolism and excretion, etc. are almost similar, with little difference. Both are also basically the same in terms of antihypertensive strength. The only difference is that in case of hypertension combined with nephropathy, or hypertension combined with type 2 diabetic nephropathy, or other renal disease, it is more appropriate to prioritize Irbesartan. And if it is hypertension combined with heart failure, hypertension combined with myocardial infarction, or hypertension combined with other heart disease patients, the selection of valsartan is more appropriate.

Talk about it from a clinician's perspective.

Irbesartan and valsartan, both angiotensin II receptor antagonists(ARBs, "sartans"), which currentlyCommonly used first-line antihypertensive drugsThe name of the original drug Irbesartan is Ambovir, and the combination preparation with the diuretic hydrochlorothiazide is Ambronol. Irbesartan original drug is called "Ambevi", and the compound preparation with the addition of the diuretic hydrochlorothiazide is called "Ambeno"; valsartan original drug is called "Daiwen", and the one with the addition of hydrochlorothiazide is called "Fudaiwen". The original valsartan drug is called "Dyven" and the one with hydrochlorothiazide is called "Fodavine", and there are many more names for generic drugs.

These two drugs are by blocking the body's "angiotensin II receptor" and play a role in lowering blood pressure, the general classification of drugs, the mechanism of action, adapt to the population, contraindications, etc. are the same, only the structure of the drug is different, in the absorption, metabolism pathway and some of the action of the target point of the difference, the details are different. However, although the same "sartan" class of drugs, whether the efficacy is exactly the same, but also need to confirm the results of large-scale clinical studies.

Based on the findings of clinical evidence-based medicineThe clinical efficacy of these two drugs is focused in addition to lowering blood pressure. Many pharmacologists have already answered questions about the pharmacological effects and drug metabolism of the two drugs. As a clinician, we will talk about these two drugs from the perspective of clinical drug selection for hypertensive patients, mainly based on the findings of evidence-based medicine, so that we can be more targeted to individualize the use of drugs for patients.

The same antihypertensive treatment will not be mentioned, but mainly theOptions for hypertensive patients with other comorbidities。

【valsartan (loanword)] Valsartan has clinical studies in patients with heart failure, and the results confirm that valsartanBeneficial in the treatment of patients with heart failure, thepossibleImprovement of cardiac function，Reducing mortality in patients with heart failure. Therefore.Valsartan can be used in patients with hypertension combined with heart failure, or after myocardial infarction and heart failure, when the "sartan" class of drugs is used.. There is also a new drug synthesized from valsartan and other drugs for the treatment of heart failure, "sacubatriz valsartan" (Nosinotropic), which is already in clinical use. Other "sartans" with cardiovascular benefits include cloxartan (left ventricular hypertrophy) and timosartan (coronary artery disease), and candesartan.

【Irbesartan] Clinical studies have confirmed that IrbesartanIn hypertension, or hypertension combined with diabetesProteinuria (microalbuminuria) is present in theStronger urinary protein (microalbumin) lowering effect in patientsThe general use of the300mg/dayIt can significantly reduce microalbumin in patients' urine. Therefore, it is especially suitable for patients with hypertension combined with microalbuminuria, hypertension combined with diabetes mellitus, and also for the treatment of diabetic nephropathy or other kidney diseases to reduce urinary protein. It is important to know that increased urinary microalbumin is a sign of early kidney damage in patients with hypertension and diabetes, and the end result of kidney damage is end-stage renal disease (uremia), so early attention should be paid to prevention and treatment. The best "sartan" type of drug to reduce urinary protein is chlorosartan potassium.

What's more, in studies of antihypertensive treatment in hypertensive patients, it has been found that in theReducing the incidence of stroke in hypertensive patientsMiddle."Sartans" are superior to calcium antagonists ("diphenhydramine") and angiotensin-converting enzyme inhibitors ("prilosec").In the irbesartan group, the incidence of stroke was lowest compared with the other sartans, followed by valsartan.

(Image from the Internet)

This is a good question that raises the heartfelt question that many hypertensive patients want to ask. Today, Dr. Zhang will talk to you about this topic, hoping to help those who are concerned about this issue.

First of all, both Irbesartan and Valsartan are two sartan-type drugs that are used very much in our country. These two antihypertensive drugs are actually sartan antihypertensive drugs, which is also known as the medical term "ARB antihypertensive drugs". This type of antihypertensive drugs are used very much in these years, the main reason is still good antihypertensive effect, at the same time both heart, brain and kidney protection. In fact, there is a reason that many people ignore, that is, Prilosec antihypertensive drugs often cause cough as a side effect, so because of this adverse reaction, so Prilosec antihypertensive drugs close relatives of sartans antihypertensive drugs more and more use.

So who is better, Valsartan or Irbesartan? Strictly speaking, different conditions, different patients, they may be adapted to different sartans, that is to say, some people may be better off with valsartan, while others may be better off with irbesartan, this is definitely different from person to person, and cannot be generalized. In more general terms, it means that what works well for you may not work well for someone else, and each person's situation is different, and they may be on a different medication that is more appropriate. However, the difference between valsartan and irbesartan is something we can explain to you.

Valsartan eat into the body after the drug peak time of about 2 hours, while the drug half-life in about 9 hours, the maximum dose a day can eat 160mg, that is, 80mg a piece of valsartan, up to two a day. And Irbesartan eat into the human body after the drug peak time of about 1 hour, while the drug half-life in about 15 hours, the maximum dose a day can eat 300mg, that is, 150mg a piece of Irbesartan, up to a day can eat two.

Here I say my own drug feeling, in the clinic if according to 80mg valsartan and 150mg Irbesartan to compare, the drug lowering strength Irbesartan to be greater, and valsartan's lowering strength is more moderate. And this difference, you can give different drugs according to the situation of different patients, for example, some people with hypertension is more serious, need Irbesartan this kind of antihypertensive effect of better drugs, and some people with a mild degree of elevated blood pressure, can not stand stronger antihypertensive drugs, then you can use the antihypertensive effect of the relatively gentle valsartan.

This is my answer to this question, and I hope that Dr. Zhang's answer will help those who have questions about this issue. Finally, I hope that every hypertensive patient can choose a suitable antihypertensive drug use program under the guidance of the doctor.

For more information about this reliable antihypertensive drugs, you can click on the following "Zhang Dafu do antihypertensive drugs course" to get: Zhang Dafu do antihypertensive drugs course

Valsartan and Irbesartan are two commonly used clinical sartan antihypertensive drugs, and patients often ask which of these two drugs is better. In fact, each drug has its own advantages and shortcomings. Only according to the patient's disease condition individualized selection, will play the maximum effect. I will introduce the difference between the two drugs.

Different chemical structures

Sartans antihypertensive drugs are classified according to their chemical structure as diphenyltetramidazoles, non-diphenyltetramidazoles, and heterocyclics.

Diphenyltetramidazoles: e.g., chlorsartan, irbesartan, telmisartan, candesartan, ali-sartan, etc.

Non-diphenyltetramidazole: e.g. irbesartan.

heterocyclic (chemistry): e.g. valsartan, etc.

Sartans all have benzpropylimidazole ring, but each drug due to the modification of the imidazole ring is different, resulting in different physicochemical properties, such as lipid solubility, tissue penetration, affinity for the receptor and so on, there are differences, therefore, the antihypertensive effect of the different sartans is also different. Irbesartan unique cyclopentyl structure and the bottom of the pocket structure of the AT1 receptor closely embedded structural stability, high affinity, low dissociation, Irbesartan AT1 blocking effect is more potent, more durable.

Different indications

Currently valsartan is only approved in the domestic specification for the treatment of mild and moderate essential hypertension. And Irbesartan can be used to treat both essential hypertension and type 2 diabetic nephropathy combined with hypertension. While the U.S. FDA-approved indications for Irbesartan are the same as in China, the indications for valsartan can be used for heart failure, myocardial infarction in addition to hypertension. Domestic research results in the two drugs used in diabetic nephropathy showed that both groups of drugs have reduced micro-proteinuria in patients with diabetic nephropathy and antihypertensive effect, and Irbesartan is more advantageous than valsartan in lowering blood pressure.

Differences in the duration of drug action

Although both drugs are given once daily, valsartan has a half-life of 6 hours and irbesartan has a half-life of up to 11-15 hours, making irbesartan's antihypertensive effect longer-lasting and smoother.

Applications for impaired renal function

Since only 30% of valsartan is renally excreted, no dose adjustment is required in patients with mild to moderate renal impairment. No dosing data are available for patients with severe renal impairment (creatinine clearance <30 ml/min). Less than 2% of the dose of irbesartan is excreted in the urine as a prototype. The pharmacokinetic parameters of Irbesartan are not significantly altered in patients with renal impairment. Therefore, no dose adjustment of the product is required in patients with renal impairment.

Effect of food on drug absorption

Diet has no effect on the absorption of Irbesartan and does not significantly affect its bioavailability. Therefore, it can be taken on an empty stomach or with a meal. And taking valsartan with food reduces the absorption by 48%, but the blood concentration after 8 hours is similar whether or not it is taken with food. In other words, the reduction in absorption has no significant effect on clinical efficacy, so valsartan can be taken with meals or on an empty stomach.

Drug-drug interactions

Since valsartan is hardly metabolized, no clinical interactions have been found with drugs that induce or inhibit the cytochrome P450 system. Irbesartan, on the other hand, is mainly metabolized oxidatively by the cytochrome P450 enzyme CYP 2C9, and therefore, care needs to be taken when co-administering with warfarin, toluenesulfonylurea, nifedipine, and rifampicin.

In short, valsartan and irbesartan are both more effective drugs for the clinical treatment of hypertension, the specific choice of which needs to be individualized according to the patient's situation.

Irbesartan and valsartan both belong to the sartan class of antihypertensive drugs, and in pharmacological classification they are both vasotocin II receptor antagonists.

Angiotensin binds to angiotensin II receptors on vascular smooth muscle, adrenal glands, and other tissues to produce a vasoconstrictor effect. Sartans block this binding, causing blood vessels to dilate and exerting a blood pressure-lowering effect.

Irbesartan and valsartan in fact there is no absolute which one is better, they will have some differences in pharmacokinetics, due to individual differences, different people use, the effect of the role of the effect and side effects may also be different. Below I specifically introduce the difference between Irbesartan and Valsartan.

1. The chemical structure of Irbesartan belongs to the class of dibenzyltetramidazole, while valsartan belongs to the class of non-heterocyclic. Irbesartan bioavailability is higher, Irbesartan bioavailability is 60%-80%, valsartan bioavailability is 23%. Irbesartan has a stronger angiotensin II receptor blocking effect than valsartan, so the antihypertensive effect is relatively stronger.

2. Food has no effect on the absorption of Irbesartan, and it has an effect on the absorption of valsartan, which can reduce the absorption by 40%, so valsartan is better when taken half an hour before meals or 1-2 hours after meals, and Irbesartan can be taken at any fixed time before or after meals.

3. Irbesartan needs to be metabolized by the hepatic drug enzyme CYP2c9, while valsartan does not need to be metabolized by the hepatic drug enzyme, so valsartan has fewer interactions with other drugs compared to irbesartan.

4. There is a difference in the peak ratio of blood concentration after using these two drugs, 69-70% for valsartan and greater than 60% for irbesartan. The larger the trough-to-peak ratio, the smoother the blood concentration, so usually valsartan is relatively smoother in lowering blood pressure.

5. Valsartan is mainly cleared by the kidneys, while irbesartan is mainly metabolized by the liver and excreted through the feces, so irbesartan can be preferred for people with renal insufficiency, and valsartan can be preferred for people with hepatic insufficiency.

6. Irbesartan has a half-life of 11-15 hours and valsartan has a half-life of 7 hours, so irbesartan can be used once a day while valsartan may need to be used twice a day.

I'm Pharmacist Anonymous, click to follow and I'll share more of my drug knowledge with you.

Irbesartan (the original drug called Ambevi) and valsartan (the original drug called Dyvan) are antihypertensive drugs angiotensin II receptor antagonists ("sartans"), they are all antihypertensive drugs of the latter, it can be said that antihypertensive effects are each elite.

They can more fully and effectively block the vasoconstrictive, water-sodium retention and organ remodeling effects of angiotensin II, and the antihypertensive effect is enhanced as the dose increases, with a wide therapeutic dose window. The most important feature is that there are fewer adverse reactions directly related to the drug, and they generally do not cause the dry cough side effects of the angiotensin-converting enzyme inhibitor ("prilosec") class of drugs, so compliance with ongoing treatment is high.

I. Their pharmacological effects

Irbesartan is used in the clinic after valsartan, i.e., Irbesartan is a "sartan-type" antihypertensive drug that has been further improved and developed after valsartan was used in the clinic.

1, Irbesartan has a stronger, more sustained and smoother antihypertensive effect, as its half-life reaches more than 10 hours. It has no significant effect on patients with renal impairment. In addition to lowering blood pressure, it is also used in the treatment of type 2 diabetic nephropathy combined with hypertension, especially in reducing micro-proteinuria in patients with diabetic nephropathy, which is more advantageous, with the same effect of antihypertensive drugs such as chlorosartan potassium.

2, valsartan half-life of 6 hours, the relative action time is short, its almost not metabolized, not found with the induction or inhibition of the cytochrome P450 system of drugs occurring with the effect of the combination of Irbesartan and some drugs (such as liver enzymes metabolized by some of the drugs warfarin, nifedipine and so on) need to be paid attention to the drug interactions. In addition to antihypertensive drugs, can also be used for heart failure, myocardial infarction, etc., also used in patients with kidney disease caused by proteinuria treatment.

As a patient, the selection of antihypertensive drugs to be suitable for their own is the best antihypertensive drugs, drug action is theoretically derived from all hypertensive people group, while the practice is for the role of the individual.

Local drugs are which is convenient to buy, can not say which drug is better, all go to peptide a certain drug, only to use another drug, the effectiveness of the drug is not good for the individual or not particularly useful, not convenient to buy and reimbursement is also more than worth it.

When a doctor gives a patient one of the above drugs, he or she will have the patient follow up and have a physical examination on a regular basis to observe the drug effect and side effect situation, and make appropriate adjustments according to the condition if necessary. For example, theoretically, according to the pharmacological effects of the choice, the effect is good, few side effects, no need to adjust.

If cha is not in line with the theory, certainly need to be adjusted (because everyone reacts differently to drugs). Therefore, hypertensive patients with medication, it is recommended to observe the drug under the guidance of a specialized doctor to lower blood pressure and protect the hypertensive target organs, in order to rest assured that it is safe!

Irbesartan and valsartan are both commonly used in the clinic of sartan antihypertensive drugs, although they are called "sartan", but due to the different structure of the drug, its efficacy, indications, metabolic pathways, etc., or there are differences, today we will discuss these two drugs with you.

Mechanism of action of sartans and the population for which they are indicated

The mechanism of action of sartans is similar, mainly by blocking the AT1 receptor, thereby antagonizing the potent vasoconstrictive effect and sodium retention caused by angiotensin II. Simply put, they can dilate blood vessels and also promote sodium excretion, thus achieving the effect of controlling blood pressure.

Sartans are indicated in cases of cardiac insufficiency, left ventricular dysfunction, post myocardial infarction combined with hypertension, and diabetic nephropathy combined with hypertension. Switching to sartans is also generally recommended for patients who are intolerant to Prilosec. Sartans reduce the risk of stroke in hypertensive patients with diabetes mellitus, atrial fibrillation, left ventricular hypertrophy, and carotid endosclerosis.

Focusing on the difference between the two drugs

1. Slight variations in antihypertensive effect and indications:

Valsartan is mainly used in patients with mild-to-moderate essential hypertension, while the indication of Irbesartan is patients with essential hypertension, and should also be used in the treatment of type 2 diabetic nephropathy combined with hypertension. In terms of the effect of the recommended dose of the two drugs, irbesartan is slightly stronger than valsartan, with a higher rate of blood pressure attainment.

2. Recommended doses vary:

The recommended dose of valsartan is 80mg, and the recommended dose of irbesartan is 150mg. Irbesartan is recommended to be taken at a reduced dosage of 75mg for those undergoing hemodialysis and for those over 75 years of age, while valsartan does not need to be reduced for elderly use.

3. Different rates of drug absorption:

Both valsartan and irbesartan work in the body in their original form, with valsartan having a bioavailability dimension of 23%, and irbesartan being a bit higher at 60-80%. This may also be one of the reasons why Irbesartan has a slightly stronger antihypertensive effect than Valsartan.

4. There are differences in the half-life of drugs:

Both drugs are once-a-day medications, but valsartan has a half-life of 9 hours, while irbesartan has a half-life of 11 to 15 hours, so irbesartan tends to have a smoother blood pressure lowering effect over a 24-hour period.

5. Drugs are metabolized by different routes:

Valsartan is not metabolized by hepatic enzymes, so interactions with other drugs are rare, and although most of valsartan is bound to plasma proteins, no interactions have been found with other plasma protein-bound drugs such as furosemide and farfarin;

Irbesartan is mainly metabolized by hepatic CYP2C9, therefore, although the drug insert does not indicate clinical data on relevant drug interactions, care should be taken when applying drugs metabolized by the same pathway, such as rifampicin, nifedipine, farfarin, and toluenesulfonylurea.

Irbesartan (trade name: Ambevi) and valsartan (trade name: Devin) are a class of drugs, both essentially belong to the angiotensin II receptor antagonist. It is difficult to distinguish between the two.But from the current small sample of clinical drug observation, in the treatment of hypertension, Irbesartan seems to be slightly better than valsartan; in reducing the risk of cardiovascular disease, valsartan is better than Irbesartan; in the treatment of diabetic nephropathy to protect the kidneys, there seems to be no difference; in terms of adverse reactions, there is no difference in the rate of occurrence of the two. Overall, the two are comparable, and it is difficult to distinguish between them.

What other angiotensin II receptor antagonist drugs are commonly used?

Angiotensin II receptor antagonists have been widely used in the clinic since the 1990s. In addition to irbesartan and valsartan drugs, other similar drugs are also used in the clinic, such as valsartan potassium hydrochlorothiazide tablets (trade name: Fodavone), which is mainly used in the treatment of hypertension; tilmisartan (trade name: Mecasin), irbesartan hydrochlorothiazide tablets (trade name: Ambeno) and tilmisartan hydrochlorothiazide tablets (trade name: Mecasin) can be used to control high blood pressure and the treatment of chronic heart failure; this type of drug lowering pressure These drugs are smoother.

What are the adverse effects of angiotensin II receptor antagonist drugs?

The two-sided nature of all medications is that the treatment is accompanied by adverse reactions that are unrelated to the treatment.Angiotensin II receptor antagonists have the following adverse effects:1. Common adverse reactions include dizziness and headache; 2. This kind of drug can induce the blood potassium of human body to rise, so patients with hyperkalemia (blood potassium >5.5mmol/L) should use this kind of drug with caution. It is recommended that patients taking these drugs for a long period of time should have their blood potassium rechecked every 4-6 weeks; 3. These drugs can induce renal vasoconstriction, which may affect renal function to a certain extent, and it is also recommended that renal function should be rechecked at intervals in patients with severe renal insufficiency; 4. Other rare adverse reactions include skin rash, muscle aches and pains, and so on.

I hope that my answer will help you! Give me a like if you like it!

Both drugs are angiotensin II receptor antagonists and, in essence, both drugs have exactly the same antihypertensive principle.

These drugs in the clinical for hypertension or better control effect, and in hypertension combined with early renal impairment, its renal function also has a good protective effect. Most importantly, they have a good effect on the reversal of ventricular remodeling, although this aspect of the role may not be as angiotensin I converting enzyme inhibitors, but it causes less side effects, and generally can be tolerated, so the clinical application is very wide.

However, in clinical use, the two drugs still have a certain gap. The original drug of Irbesartan is called Ambevi, which is still very powerful in clinical antihypertensive effect, while the original drug of Valsartan is called Dyvan, whose antihypertensive effect is still slightly worse compared to Ambevi. Therefore, if the blood pressure is relatively high, it is more appropriate to use Ambovir.

The strongest antihypertensive effect of all the drugs in its class would be Olmesartan, which should qualify it as the strongest ARB of all time.

In fact, listening to the name, it is simple to see that these two drugs are basically the same, both belong to the angiotensin II receptor antagonist.

In the clinic, can not say which one is better, on the one hand is the habit of medication, on the other hand is personal experience, the doctor used more, naturally more experience, more certainty.

Let's talk briefly about the difference between these two drugs from a theoretical point of view.

First, the duration of the role

Irbesartan has a half-life of 11-15 hours and valsartan has a half-life of 7-9 hours, so Irbesartan is available once a day while valsartan may need to be used twice a day, but in practice valsartan once a day in the clinic is also smooth for many high blood pressures.

Second, lowering blood pressure

Irbesartan has a stronger angiotensin II receptor blocking effect than valsartan, so the antihypertensive potency is relatively stronger. However, there is a difference in the peak ratio of blood concentration after using these two drugs, 69-70% for valsartan and greater than 60% for irbesartan. The greater the trough-to-peak ratio, the smoother the blood concentration, so usually valsartan lowering blood pressure is relatively smooth.

Third, drug interactions

Irbesartan is metabolized by the hepatic enzyme CYP2c9, which is not required for valsartan, so valsartan has fewer interactions with other drugs compared to irbesartan. And Irbesartan needs to be taken care of when combined with warfarin, toluenesulfonylurea, nifedipine, rifampicin.

Fourth, metabolism

Valsartan is mainly cleared by the kidneys, while irbesartan is mainly metabolized by the liver through fecal excretion, so irbesartan can be preferred for people with renal insufficiency, and valsartan can be preferred for people with hepatic insufficiency. But all need to be careful, especially renal insufficiency, sartan itself is a double-edged sword, both can protect renal function, but when renal function deterioration will also aggravate the deterioration of renal function.

All their own companies have done relevant research, naturally, the upfront investment is needed, we only look at the conclusions.

1, Valsartan has a clinical study for patients with heart failure, the results confirm that valsartan has a beneficial effect on the treatment of patients with heart failure, can improve cardiac function and reduce the morbidity and mortality of patients with heart failure.

Therefore, in hypertension combined with heart failure, or after myocardial infarction, heart failure patients choose "sartan" class of drugs, you can choose valsartan, the study also showed that valsartan is beneficial to atrial fibrillation.

2, Irbesartan in hypertension, or hypertension combined with diabetes mellitus proteinuria patients to reduce the role of urinary protein, can significantly reduce the patient's urine microalbumin.

Clinical Applications.

1. If you have high blood pressure, you can take both, your blood pressure says so, and you can continue to take them if your blood pressure is stable.

2、If you have coronary heart disease or combined heart failure, you can choose valsartan.

3、If you have diabetes and proteinuria, you can choose Irbesartan.

So, overall, there's no essential difference, it's pretty much the same, the key is to always remember to use a sartan when it's time to use a sartan!